Juventas Therapeutics Receives $22,200,000 Series B Financing

  • Feed Type
  • Date
    7/17/2012
  • Company Name
    Juventas Therapeutics
  • Mailing Address
    10000 Cedar Ave. Cleveland, OH 44106
  • Company Description
    Juventas Therapeutics is a privately held biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. The company’s lead product, Stromal–cell Derived Factor 1 (SDF–1), has been shown to protect and repair tissue following organ–damage in a broad range of pre–clinical disease models.
  • Website
    http://www.Juventasinc.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $22,200,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds will fund completion of ongoing Phase II clinical trials investigating the use of JVS-100 in treating patients with chronic heart failure or critical limb ischemia.
  • M&A Terms
  • Venture Investor
    Triathlon Medical Ventures
  • Venture Investor
    Fletcher Spaght Ventures
  • Venture Investor
    Reservoir Venture Partners
  • Venture Investor
    Early Stage Partners
  • Venture Investor
    Takeda Ventures
  • Venture Investor
    Venture Investors
  • Venture Investor
    Glengary
  • Venture Investor
    Tri-State Investment Group
  • Venture Investor
    Global Cardiovascular Innovation Center

By posting a comment, you agree to our terms and conditions.